ANAGRELIDE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Anagrelide Hydrochloride, and when can generic versions of Anagrelide Hydrochloride launch?
Anagrelide Hydrochloride is a drug marketed by Barr, Chartwell Rx, Impax Labs, Ivax Sub Teva Pharms, Natco Pharma Usa, Rising, Roxane, Torrent, and Watson Labs. and is included in nine NDAs.
The generic ingredient in ANAGRELIDE HYDROCHLORIDE is anagrelide hydrochloride. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the anagrelide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Anagrelide Hydrochloride
A generic version of ANAGRELIDE HYDROCHLORIDE was approved as anagrelide hydrochloride by IMPAX LABS on April 18th, 2005.
Summary for ANAGRELIDE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Clinical Trials: | 23 |
Patent Applications: | 787 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANAGRELIDE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ANAGRELIDE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Celgene | Phase 3 |
PharmaEssentia | Phase 3 |
Brightech International | Phase 3 |
Pharmacology for ANAGRELIDE HYDROCHLORIDE
Drug Class | Platelet-reducing Agent |
Mechanism of Action | Phosphodiesterase 3 Inhibitors |
Physiological Effect | Decreased Platelet Production |